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Each year millions of pounds is spent on cancer research,
and much of this goes towards trying to improve treatment.
Randomised clinical trials are carefully planned and set up.
Hopes may be high for the new treatment. But in many
cancer trials, because patient recruitment may extend over
several years, data are beginning to accrue whilst new
patients are still being entered. If the evidence seems to be
going in one direction, then there is a potential conflict of
interest between the patients about to be randomised to what
seems to be the inferior treatment, and the wider interests of
obtaining reasonably definitive results.
One trial which did stop early was a trial set up to
compare the promising new high energy neutron therapy
with conventional photon therapy for four pelvic tumours
(Errington et al., 1991). This trial started in February 1986.
In preparation for a mid-term review of the Medical
Research Council (MRC) neutron therapy research pro-
gramme by a MRC subcommittee, an ad hoc analysis of
mortality and morbidity was prepared in October 1989. This
was intended mainly as a check on data quality. Because the
mortality was much worse in the neutron patients than in the
photon patients, there were concerns about the ethics of
continuing the trial, and the neutron therapy subgroup
recommended the setting up of an independent Data
Monitoring Committee (DMC). A fuller analysis was under-
taken. In the light of these results, randomisation was
suspended. This decision was then ratified by the DMC, and
subsequently approved by the MRC's Cancer Therapy Com-
mittee.
This experience raises many issues, among them the lack of
planning for the possibility of adverse results, whose respon-
sibility it was to monitor the trials, the timing of the setting
up of the DMC, and, as a result of these, the dilemma of a
clinician, party to interim results, having to decide whether it
was ethical to continue to randomise patients.
A trial of a radiosensitiser in conjunction with
radiotherapy, as opposed to radiotherapy alone (MRC
Working Party on Advanced Carcinoma of the Cervix, 1993)
also stopped early. This trial started in October 1986, with
regular interim analyses planned from the outset. The interim
analysis in April 1989 indicated a formal review was
required. This again led to the trial coordinator feeling
unable to continue randomisation. Recruitment was
suspended two months later, and the trial closed in
November 1989 by the MRC Cancer Therapy Committee,
although patients had not been entered for several months
before that. The problems were similar to those in the neut-
ron therapy study, with local recurrence being worse in the
new treatment group. Details of the data monitoring of both
trials are discussed by Parmar and Machin (1993).
For both the trial of high energy neutron therapy, and the
radiosensitiser trial, the decision to stop has been well-
documented. However, many randomised trials stop short of
their intended accrual for less clear-cut reasons. The dilemma
that can result when trials stop early is illustrated by Meier
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(1979), who cites three trials of simple versus radical mastec-
tomy for breast cancer. A Danish study- (Kaae & Johansen,
1962), found no difference in survival chances. A study from
Cambridge (Brinkley & Haybittle, 1966) of stage II patients
stopped after a preliminary analysis, because the simple
mastectomy group were faring better. Bearing in mind the
results of the previous trial, the investigators felt that the
study was unlikely to demonstrate a difference in favour of
radical mastectomy and so it was unethical to carry on
randomising patients. However, a study from London
(Atkins et al., 1972), whilst finding no difference in stage I
patients, found a difference in 10 year survival in stage II
patients, this time in favour of radical mastectomy. The trial
was stopped for stage II patients as a consequence of these
results. Was the evidence from either study really so compell-
ing that randomisation had to be stopped? Meier comments
that these studies are indicative of a shift that happened
between the 1950's and the 1970's towards protecting the
individual patients' interests sometimes at the expense of
obtaining clear cut scientific results.
Has a more balanced approach developed in recent years?
In a review of 45 randomised trial reports in the British
Medical Journal, the Lancet and the New England Journal of
Medicine (Pocock et al., 1987), most trials did not even
mention intended sample size, nor any policy on stopping or
publication, and only five trials mentioned explicit stopping
rules. More recently, we reviewed the British Journal of
Cancer, and in 1991 and 1992 there were 16 first reports of
randomised phase III trials. Eight made no mention of
intended sample size or power calculations. Six of these came
out with little conclusive evidence of differences between
treatments, although interpretations of 'equivalence' or
preference for one treatment varied. Three reports had a post
hoc discussion of power, two of which had reached target,
the third having been stopped after early results. Of the five
trials which reported proper planning, one met its target,
three exceeded target, and one was stopped early because of
long term survival results from an associated pilot study.
Only one paper mentioned any monitoring arrangements,
although typically the trials were accruing patients for
between three and five years, which means that data were
accruing whilst new patients were still being randomised.
There is no suggestion that any of these trials should have
stopped any earlier, but for the trials that did not report
intended sample size, it would aid interpretation to know
why they stopped recruiting when they did.
Outline ofmain issues in monitoring trials
The key decision for any potential trial is whether to start it.
This means assessing the potential benefits and drawbacks of
a new treatment policy compared to the standard, deciding
what the benefits would need to be in order to change clinical
policy, estimating the trial size needed to demonstrate such
benefits, and then seeing whether such a trial is feasible. This
will involve review of the existing evidence, practical con-
siderations such as the rate at which patients with the
relevant condition appear, and strategic decisions about
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which are the most important trials to be doing at a given
time.
Having made the decision to embark on a trial, a decision
to stop it prematurely should not be taken lightly. There are
several good reasons (Pocock, 1983) for monitoring the pro-
gress of a trial. These include checks on protocol compliance
and data management, so that remedial action can be taken
while the trial is still in progress, as well as monitoring
outcomes such as mortality and treatment toxicity in case it
becomes necessary to stop the trial.
The main reasons for stopping a trial early are that there is
a conclusive result on the main endpoint from this trial or
independent trial(s), an inconclusive result on the main end-
point with no chance of achieving conclusive results, or the
emergence of serious side effects on one of the treatment
arms. In anticipation of such possibilities, the investigators
can set up formal rules as a guide for when to stop the trial.
The chief advantages of considering early stopping are that
this can lead to a reduction in expected sample size, if there
is a large difference in effectiveness, and the results can be
disseminated sooner with consequent benefits for current
patients (Fleming & Watelet, 1989). The disadvantage of
early stopping is that one is left with an incomplete picture
of the relative benefits of the treatments, because of less
precise and possibly exaggerated estimates of effect, and
because of short follow-up. Machin (1992) argues that it is
unethical to stop a trial if by so doing it leaves a high level of
uncertainty about the magnitude of the benefit of a new
treatment.
A trial of high-dose radiotherapy with or without induc-
tion chemotherapy for stage III non-small cell lung cancer
(Dillman et al., 1991) stopped early because of improved
survival for the group who also received chemotherapy. This
decision has been criticised (Souhami et al., 1991) because of
the imprecision of a potentially overestimated treatment
effect. The investigators (Propert et al., 1991) felt it was
unethical to continue to randomise patients to what they felt
was an inferior treatment. The wider clinical community
(Tannock & Boyer, 1992) are waiting for replication from
other trials before being completely convinced. The debate
over this trial highlights again the fundamental dilemma
(Pocock, 1992), which is to balance the ethical considerations
for the individual patients in a particular trial, which imply
stopping randomisation as soon as one treatment emerges as
being preferable, versus the collective ethics of the com-
munity who need accurate information of the benefits and
costs of the treatment.
Statistical issues in monitoring trials
For statisticians, development of plans for sequential trials
has been a rich area. Early work was on fully sequential
plans, which assume that the results can be updated with
each new patient or pair of patients. A more recent develop-
ment are group sequential plans (Pocock, 1983), which fit
more neatly with the constraints of practical clinical research.
These plan for a small number of analyses to occur, for
example, either after fixed numbers of patients have been
entered, a fixed number of deaths have been notified, or
appropriately spaced in calendar time. Recent
methodological work, simulating a sequential analysis based
on two MRC randomised trials in patients with small-cell
lung cancer, appears in this issue (Donaldson et al., 1993,
Whitehead, 1993). There is a growing recognition that these
serve as guide-lines rather than formal stopping procedures,
as the decision to stop a trial will be influenced by several
factors, including both safety and efficacy considerations, and
evidence external to the trial, such as the reporting of related
studies.
When using the group sequential approach, a key decision
is how many analyses to plan for a trial. There are big gains
to be had in going from one to two analyses (Geller &
Pocock, 1987), but there is little point in going above five
unless an extremely large difference is anticipated, which is a
very rare occurrence in cancer therapy. There are different
stopping guidelines available (Emerson & Fleming, 1990),
although Machin (1992) argues that Peto's simple rule of
using P<0.001 for all but the last analysis which is done at
P<0.05 reflects the reality of trial experience. Conven-
tionally, all of them are structured in a similar way, with
individual decision for each analysis being made at relatively
stringent levels of statistical significance, which preserves the
overall level of significance for the whole trial. This 'spending
P-values' can seem a little artificial, and these rules can
alternatively be interpreted, perhaps more intuitively, as a
formal balancing of the current trial data with previous data
and/or beliefs (Freedman & Spiegelhalter, 1989), with
different rules corresponding to different prior beliefs about
the relative efficacy of the treatments. Taking this approach,
the investigators can formally quantify their initial position,
for example, as 'sceptical' (Spiegelhalter et al., 1992), which
means that strong evidence from the trial is required before
superiority of one of the treatments is considered to be
established.
Although significance testing may be a useful guide to
when to stop a trial, the primary purpose of the trial is to get
an unbiased estimate of treatment effect. A problem with
stopping a trial early is that a trial is likely to be stopped at a
point where the estimated effects happens to be large. As a
result, the estimated effect from a trial that has just stopped
early will be biased. It is possible to make an adjustment for
this, if the investigators can quantify their prior beliefs about
the effectiveness of the treatment (Pocock & Hughes, 1989).
Particular dilemmas occur when a trial has a complex
design, or similar trials are running in parallel. Such a trial,
for adjuvant therapy of resected carcinoma of the colon with
two treatments was reported by Moertel et al. (1990).
Patients with stage B2 cancer were randomised to observation
or levamisole combined with fluorouracil. Patients with stage
C were randomised to either observation, levamisole or
levamisole combined with fluorouracil. The trial stopped and
the results were reported because the stage C patients were
performing better on the combined treatment. The authors
felt able to make definite recommendations for this group,
but needed more follow up for the B2 patients. If this was
essentially one trial, it should not have stopped because of
results in a subgroup. If there were two separate trials, why
was the B2 trial apparently terminated early on the basis of
the C patients results? As this trial had finished accrual, the
implications of the decision to stop were primarily for
regulatory purposes and the planning of further trials (Flem-
ing, 1992). This raises the more general question of the best
time to publish results of a trial that has finished recruitment
(Altman & Machin, in press).
In fact, an overview in this journal (Gray et al., 1991),
shows these results to be the most dramatic out of 13 similar
trials, suggesting the results in this study are by chance an
overestimate of a rather more modest effect, and much larger
trials are needed to make a proper assessment. Such a trial,
the Adjuvant X-ray and 5FU Infusion Study (AXIS), is
currently recruiting patients, and it is important that 'early'
results from small trials do not compromise potentially
definitive trials.
Practicalities to consider when setting up a trial
Trials need to be carefully monitored, so that decisions to
stop early, whether based on trial data or external evidence,
can be properly made and documented.
What, in practical terms can be done? First, make a realis-
tic assessment of possible scenarios, using general experience
from cancer trials. Rigorous assessment of directly relevant
trials should be carried out, using techniques such as meta-
analysis (Thompson & Pocock, 1991; Parmar & Altman, in
press). Subjective beliefs about the likely relative efficacy of
the treatments, and the clinical benefits that would be
required before a new treatment would be used routinely can
also be documented at this stage, although these can be
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of treatment for superficial bladder cancer (Freedman &
Spiegelhalter, 1983).
Mechanisms for stopping the trial must be identified, with
lines of communication and responsibilities well-defined.
Ideally this will involve a separate DMC, although this will
not be feasible in every trial. The MRC are moving towards
DMC's responsible for groups of trials in certain areas (Par-
mar & Machin, 1993), and there is one formally constituted
to oversee the trials of the MRC Leukaemia Working Party.
The Cancer Research Campaign are following a similar
strategy, and now, for example, have a DMC for their breast
cancer trials.
In cancer trials there will typically be relevant data on
mortality, toxicity, metastases, and regression and progres-
sion. Good data management is essential, using appropriate
software such as COMPACT (COMPACT Steering Group,
1991). Even with good data-management there can be time
lags in information flow, and this is documented for the trial
of a radiosensitiser in cervix cancer already referred to here
(MRC Working Party on Advanced Carcinoma of the Cer-
vix, 1993).
The criteria for stopping a trial should be explicit. Mor-
tality and excess toxicity are obvious endpoints to monitor,
but more complex features such as quality of life are much
more difficult to assess and analyse (Fletcher et al., 1992;
Olschewski, in press). A particular dilemma arises when con-
sidering which endpoints to monitor because only short-term
results, such as tumour response, acute morbidity and early
deaths, are available quickly, whereas the real value of many
trials is their potential to give information on long term
survival and late morbidity. By definition, decisions to stop
have to be made primarily on the early information, and it is
of importance to assess to what extent this can act as sur-
rogate information for the longer term outcomes (Ellenberg,
in press). Monitoring for toxicity is always worthwhile, but
monitoring for efficacy is likely to be most beneficial when
mature data are accruing fast relative to the entry of new
patients.
If a trial does stop early, what are the priorities? The
surviving trial patients should be informed of the position,
which will be much easier if they gave genuinely informed
consent. When news of the neutron therapy trial's closure hit
the press, the hospital switchboard was jammed with calls
from concerned patients. It is a tribute to the clinicians
involved that none of those calls were from trial patients,
who by that time had been individually counselled. For these
trials, the treatment was short-term, but for patients in trials
of longer term therapy, consideration of appropriate treat-
ment changes is an issue. The next priority should be the
release of full results, quickly, via peer-reviewed journals
(Pocock, 1992), although this is difficult given the current
constraints of most journals.
Membership of DMC's is critical. There should be experi-
enced, knowledgeable triallists, with both clinical and statis-
tical expertise. Pocock (1992) suggests a clinical chairman
with another clinician and a statistician, and this is the
strategy adopted by the MRC (Parmar & Machin, 1993).
There is sometimes a problem finding clinicians who are not
already entering patients into the trials. A dilemma is
whether industry employees should sit on the DMC's for
their own trials. Hampton and Julian (1987) feel that DMC's
should be seen to be entirely independent of the companies,
and yet if there is a problem with drug safety, company
people have access to other data, and expertise that may be
valuable. One solution is to allow the DMC to seek advice
from whoever they consider appropriate. When deciding
membership of DMC's, it is worth remembering that many
individuals in the pharmaceutical industry have years of
experience in trials, and for trials of surgery and
radiotherapy, there is no conflict of interest. However DMC's
are set up, their membership should be 'public knowledge',
and the balance between confidentiality of trial results, com-
mercial or other vested interests and accountability for
decision making needs to be carefully thought through.
Does every trial need to be monitored by a DMC? Fleming
(1992) recommends that DMC's should be established in
randomised trials diagnosed to definitively establish safety
and efficacy, particularly for diseases that are life-threatening
or produce irreversible morbidity. There is always a balance
of costs versus risks, including the risk that the existence of a
DMC may encourage early stopping. The potential benefit
depends on length of time to outcome versus speed of accrual
of patients. What are risks if early stopping is not con-
sidered? The major fear is the possibility of undue harm (or
lack of benefits) to trial patients. If the trial is not blind, as
has to be the case with many cancer trials, suspicions of a
difference may arise among participating clinicians, and un-
planned interim analysis may lead to a dilemma. In a trial of
second-line hormone therapy versus single agent
chemotherapy (Dixon et al., 1992), it became evident that
there was no early advantage to the group randomised to
chemotherapy, although it is not clear whether this was
based on clinical observation or ad hoc analysis. The authors
say 'Having sought statistical advice, the trial was abandoned
once sufficient events had occurred to allow for sufficient
statistical power in its analysis'. It is far better to plan in
advance.
Conclusions
In running clinical trials, it is ethical to randomise patients
while there is uncertainty as to the relative benefits of treat-
ment, and there is indeed a duty to carry on doing so until
firm evidence emerges as to which treatment is better. This is
often interpreted at the level of the individual clinician, but
Freedman (1987) has advocated the concept of clinical
equipoise, which says that even if an individual doctor has
preferences for one treatment, it is ethical to randomise while
genuine uncertainty remains in the clinical community about
the relative merits of treatments. When setting up a trial the
protocol should always discuss arrangements for monitoring
the trial, or justify lack of monitoring. The mechanisms in
place should be appropriate, given the trial arrangements and
the likely impact of the trial. Above all, in the excitement of
the possibility of improving cancer care, triallists should also
anticipate other possible outcomes.
Fifteen years ago, Pocock (1978) wrote an article for this
journal on size of trials and stopping rules. This editorial
says nothing fundamentally different to what he said then.
However, as recent trials demonstrate, it is timely to say it
again. Most trials do not need to stop early, but for the
protection of the trial patients, and the future patients whose
treatment may be influenced by current trials, data monitor-
ing should be an integral part of the design of cancer clinical
trials.
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